DOCSLIB.ORG

APHAR2012 Program.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
APHAR2012 Program.Pdf GENERAL INFORMATION Date: 20–21 September 2012 Location: Graz Lecture Hall B (HS 06.02) Universitätsplatz 6, 8010 Graz, Austria GRAZ, Austria, 20–21 September 2012 Nearest bus stop: Universität/Halbärthgasse (No. 41, 63) Attemsgasse/Goethestraße (No. 41, 63) Mozartgasse/Heirichstraß2 (No. 30, 31) Uni-ReSoWi/Geidorfgürtel (No. 39) Registration: Please pay the registration fee directly at the conference desk. Registration fees: Regular: EUR 30.00 Reduced:* EUR 15.00* *Reduced registration fees are applicable to students upon presentation of confirmation of student status (for confirmation form see website: http://www.aphar.at/aphar2012.html). Participation is free of charge for APHAR Honorary Members. Information All presentations shall be given in English. for Presenting Authors: Short oral communications: The duration of the presentation should be 10 minutes, followed by a 5 min discussion. The lecture room is equipped for presentations with PowerPoint (PC format): Double projections are not possible. Poster presentations: The dimensions of the poster boards are: width: 98 cm, height: 170 cm. Presenting authors are requested to attend their posters during the designated poster sessions. Abstracts: Abstracts are published in BMC Pharmacology & Toxicology, 2012; 13 (Suppl. 1) Presentation There will be prizes for Best Oral and Best Poster presentations. Prizes: The prizes will be awarded at the end of the meeting. Internet WLAN internet access will be provided for free at the meeting location. Access: Please bring your own laptop equipped for wireless internet connection. Local Department of Experimental and Clinical Pharmacology Organisers: (Medical University of Graz): Peter Holzer, Thomas Griesbacher Department of Pharmacognosy (Institute of Pharmaceutical Sciences, Karl-Franzens University of Graz): Rudolf Bauer Department of Pharmacology and Toxicology (Institute of Pharmaceutical Sciences, Karl-Franzens University of Graz): Klaus Groschner Contact: Local organisation: [email protected] 2 Austrian Pharmacological Society (APHAR): [email protected] OPENING OF THE MEETING 09:00–09:15 Opening of the Meeting Peter Holzer (President, APHAR) SHORT COMMUNICATIONS 1 09:15–10:30 Chairs: Klaus Groschner (Graz) 09:15–09:30 Uremia alters HDL composition and cholesterol efflux capacity A15 Michael Holzer, Ruth Birner-Grünberger, Tatjana Stojaković, Dalia El-Gamal, Veronika THURSDAY, 20 September 2012 Binder, Christian Wadsack, Ákos Heinemann and Gunther Marsche (Graz) 09:30–09:45 Tolerance to nitroglycerin through proteasomal degradation of aldehyde A36 dehydrogenase-2 in a genetic mouse model of ascorbate deficiency Astrid Schrammel, Gerald Wölkart, Matteo Beretta, Heike Stessel, Kurt Schmidt, Nobuyo Maeda and Bernd Mayer (Graz, Chapel Hill) 09:45–10:00 A TRPC3 blocker, Pyr3, prevents stent-induced arterial remodeling A85 Sarah König, Sara Browne, Heinrich Mächler, Gerald Höfler, C. Oliver Kappe, Toma N. Glasnov, Marlen Braune, Eric Wittchow and Klaus Groschner (Graz,Erlangen) 10:00–10:15 The anti-addiction drug ibogaine inhibits cardiac ion channels: a study to A38 assess the drug's proarrhythmic potential Xaver Koenig, Michael Kovar, Lena Rubi, Ágnes K Mike, Péter Lukács, Vaibhavkumar S. Gawali, Hannes Todt, Walter Sandtner and Karlheinz Hilber (Vienna) 10:15–10:30 A mouse model to study the C-terminal regulation of CaV1.3 L-type calcium A50 channels Anja Scharinger, Florian Hechenblaikner, Gabriella Bock, Mathias Gebhart, Kai Schönig, Dusan Bartsch, Anupam Sah, Nicolas Singewald, Martina J. Sinnegger-Brauns and Jörg Striessnig (Innsbruck, Mannheim) COFFEE BREAK & POSTER SESSION 10:30–11:00 Coffee Break & Poster Session ▪ Poster Tours for Poster Groups 1 / 5 / 9 / 13 PLENARY LECTURE I 11:00–11:45 Chairs: Rudolf Bauer (Graz), Ljiljana Gojković-Bukarica (Beograd) Alexandra K. Kiemer (Department of Pharmaceutical Biology, Saarbrücken) Targeting inflammatory pathologies – redress the balance of pro- and anti-inflammatory mediators SHORT COMMUNICATIONS 2 11:45–12:30 Chairs: Rudolf Bauer (Graz), Ljiljana Gojković-Bukarica (Beograd) 11:45–12:00 Influence of different Hypericum perforatum L. preparations on pharmacokinetic A11 and pharmacodynamic properties of pentobarbital, diazepam and paracetamol Aleksandar Rašković, Nebojša Stilinović and Momir Mikov (Novi Sad) 12:00–12:15 Last minute change: see also Naturally-occurring cyclic peptides with immunosuppressive properties P22 (A31) Christian W. Gruber et al. (Vienna) 12:15–12:30 Last minute change: see also Plant cyclotides as peptide templates for GPCR drug discovery P55 (A89) Johannes Koehbach et al. (Vienna) Thursday Programme continues on next page 3 LUNCH BREAK 12:30–14:00 Lunch Break PLENARY LECTURE II 14:00–14:45 Chairs: Ákos Heinemann (Graz), Melita Šalković-Petrišić (Zagreb) Eva Kostenis THURSDAY, 20 September 2012 (Department of Pharmaceutical Biology, Bonn) Biased seven-transmembrane receptor ligands: a way to safer medicines? SHORT COMMUNICATIONS 3 14:45–16:00 Chairs: Nicolas Singewald (Innsbruck), Dubravka Švob Štrac (Zagreb) 14:45–15:00 Antidepressant-like effects of benzodiazepine site inverse agonists in the A1 rat forced swim test Janko Samardžić and Dragan I. Obradović (Beograd) 15:00–15:15 Histone deacetylase inhibitors, glutamatergic drugs and deep brain stimulation A42 rescue resistance to fear extinction in a genetic mouse model Nigel Whittle, Claudia Schmuckermair, Ozge Gunduz-Cinar, Markus Hauschild, Francesco Ferraguti, Andrew Holmes and Nicolas Singewald (Innsbruck, Bethesda) 15:15–15:30 Dopamine transporter phosphorylation site threonine 53 regulates substrate A45 reuptake and amphetamine-stimulated efflux Jae-Wong Yang, James D. Foster, Amy E. Moritz, Sathyavathi ChallaSivaKanaka, Margaret A.Smith, Marion Holy, Kyle Wilebski, Roxanne A. Vaughan and Harald H. Sitte (Vienna, Grand Forks) 15:30–15:45 The galanin system in depression and antidepressant treatment: focus on the A75 locus coeruleus Simone B. Sartori, Anupam Sah, Baosheng Zhao, Inga Neumann, Rainer Landgraf and Nicolas Singewald (Innsbruck, Regensburg, Munich) 15:45–16:00 Neuropeptide Y modulates fear and fear extinction in distinct nuclei of the A87 amygdala Ramon Tasan, Dilip Verma, Mario Mietzsch, Regine Heilbronn, Herbert Herzog and Günther Sperk (Innsbruck, Berlin, Darlinghurst) COFFEE BREAK & POSTER SESSION 16:00–16:30 Coffee Break & Poster Session ▪ Poster Tours for Poster Groups 2 / 6 / 10 / 14 PLENARY LECTURE III (EPHAR LECTURE) 16:30–17:15 Chairs: Peter Holzer (Graz), Thomas Griesbacher (Graz) Gero Miesenböck (Wayneflete Professor of Physiology, Oxford) Optogenetics and its potential for pharmacology The EPHAR Lecture is sponsored by the European Federation of Pharmacological Societies (with support from the British Pharmacological Society) Thursday Programme continues on next page 4 GENERAL ASSEMBLY OF APHAR (parallel session) 17:15–18:30 General Assembly of APHAR (members of APHAR only) Teilnahmeberechtigt sind alle ordentlichen Mitglieder, sowie Vertreter der außerordentlichen Mitglieder. Stimmberechtigt sind nur die ordentlichen Mitglieder. Gem. § 9 der Statuten wird den Mitgliedern die vorläufige Tagesordnung spätestens vier Wochen vor der Generalversammlung zugeschickt. Weitere Anträge sind mindestens sieben Tage vor dem Termin der Versammlung beim Vorstand schriftlich einzureichen. THURSDAY, 20 September 2012 YOUNG SCIENTISTS CAREER WORKSHOP (parallel session) 17:15–18:30 Location: Lecture Room C (HS 06.03) Representatives from the Pharmaceutical Industry will give an overview of job opportunities for young pharmacologists outside the classical academic setting. Coordination and Chair: Maria Waldhoer (Copenhagen) Round Table Workshop Keynotes: Andrew J. Brown (GlaxoSmithKline, Harlow, Essex, UK): "Sailing out into the perfect storm" Maria Waldhoer (NovoNordisk A/S, Copenhagen, Denmark): "From academia to industry – a late-in-career transition" Thomas Pfeifer (Merck Group, Ausria): "Science, what else...?" Open questions/Answers Sum up RECEPTION BY THE GOVERNOR OF STYRIA 19:00–21:30 Reception by the Governor of Styria Location: Orangerie, Burggarten Entrance: Erzherzog-Johann-Allee or Hofgasse 15 (Grazer Burg) The historic Orangerie is within walking distance of the meeting venue of the 18th Scientific Symposium of APHAR: Pass the main buildings of the university on your left and walk along Halbärthgasse, then turn right into Zinzendorfgasse and follow it until you reach the Stadtpark. Cross Glacisstraße and enter the park, taking the path diagonally to the left (behind the bus stop), and follow this way until you reach Erzherzog-Johann-Allee. You can enter the Burggarten either through the gate in the garden wall between the Burgtor and Café Promenade (until 8pm) or from the third courtyard of the Grazer Burg (entrance Hofgasse 15). Participation is free of charge for registered participants of the meeting. 5 Friday Programme begins on next page SHORT COMMUNICATIONS 4 (CLINICAL PHARMACOLOGY) 09:00–10:30 Chairs: Markus Zeitlinger (Vienna), Darko Modun (Split) 09:00–09:15 A PET microdosing study with the P-glycoprotein inhibitor tariquidar A17 Martin Bauer, Markus Zeitlinger, Cécile Philippe, Johann Stanek, Wolfgang Wadsak, Markus Mitterhauser, Georgios Karanikas, Markus Müller and Oliver Langer (Vienna, Seibersdorf) 09:15–09:30 Characterization of colistin tissue pharmacokinetics by microdialysis FRIDAY, 21 September 2012 A74 Peter Matzneller, William Couet, Patrice Gobin, Markus Müller and Markus Zeitlinger (Vienna, Poitiers) 09:30–10:45 Does pulmonary
Load more

Recommended publications
  • PDF File of All Submitted Abstracts
    APHAR 2012 Abstract Preview MEETING ABSTRACTS 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Joint Meeting with the Croatian, Serbian and Slovenian Pharmacological Societies Graz, Austria, 20–21 September 2012 A1 Acknowledgements: This work was supported in part by the Antidepressant-like effects of benzodiazepine site inverse Ministry of Education and Science, Republic of Serbia, grant no. agonists in the rat forced swim test 175076. Janko Samardžić and Dragan I Obradović Institute of Pharmacology, Clinical Pharmacology and Toxicology, A2 Medical Faculty, University of Belgrade, 11129 Belgrade, Serbia Methadone-drugs interactions: possible causes of methadone- E-mail: [email protected] related deaths Vesna Mijatović1, Isidora Samojlik1, Stojan Petković2 and Nikša Background: There are three kinds of allosteric modulators acting 2 Ajduković through the benzodiazepine (BZ) binding site of the GABA 1 A Department of Pharmacology, Toxicology and Clinical receptor: positive (agonist), neutral (antagonist), and negative Pharmacology, Faculty of Medicine, University of Novi Sad, 21000 (inverse agonist) modulators. Agonists and inverse agonists 2 Novi Sad, Serbia; Department of Forensic Medicine, Faculty of commonly exert bidirectional influences on observed behavioral Medicine, University of Novi Sad, 21000 Novi Sad, Serbia parameters. In the present study we have investigated the E-mail: [email protected] modulation of behavioral responses to environmental novelty in two unconditioned paradigms: spontaneous locomotor activity (SLA) and Background: Methadone is an effective analgesic and it is widely forced swim test (FST), elicited by DMCM (methyl-6,7-dimethoxy-4- used to suppress withdrawal symptoms from other opiates. Its ethyl-beta-carboline-3-carboxylate), a non-selective inverse agonist, consumption is usually associated with concomitant drug use in in the dose range that previously did not produce anxiogenic effects heroin addicts, and this combination is a possible risk factor for and convulsions.
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Phosphoproteomics Illuminates Opioid Actions Tao Che and Bryan L
    Phosphoproteomics Illuminates Opioid Actions Tao Che and Bryan L. Roth* Department of Pharmacology, University of North Carolina School of Medical, Chapel Hill, North Carolina 27514, United States ABSTRACT: Opioids are widely used analgesic medications with a high potential for tolerance and dependence and represent a frequent cause of death due to overdose. Opioids mediate their actions via a family of opioid G protein coupled receptors. Elucidating the biochemical mechanism(s) responsible for both the therapeutic and deleterious side effects of opioids could provide a biochemical roadmap for selectively targeting therapeutic signaling pathways. Here we provide a perspective on emerging findings, which illuminate these signaling pathways via unbiased and quantitative phosphoproteomic analysis. What emerged from these studies is the discovery that certain deleterious actions mediated by the κ opioid receptors appear due to specific activation of mTOR pathways. The findings imply that designing drugs, which bypass mTOR signaling, could yield safer and more effective analgesics. pioid drugs like morphine and oxycodone are powerful with the use of dynorphin- and KOR-knockout mice, they O painkillers that produce analgesia by activation of opioid identified the phosphorylation sites uniquely related to KOR G-protein coupled receptors (GPCRs). Although opioids are activation. The authors determined that the dynamic changes quite useful for alleviating pain, they can also elicit an array of in KOR phosphorylation displayed spatio-temporal control. harmful side effects, such as aversion, hallucinations, addiction, Further analysis of KOR-mediated phosphorylation identified and death by respiratory depression. Thus, a new class of those patterns relevant to specific neuronal circuits, in nonopioid analgesics could go a long way toward alleviating particular, dopamine-, glutamate-, and γ-aminobutyric acid the prevailing opioid crisis.
    [Show full text]
  • Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2020 Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior Amelia Dunn Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons DIVERSE KAPPA OPIOID RECEPTOR AGONISTS: RELATIONSHIPS BETWEEN SIGNALING AND BEHAVIOR A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Amelia Dunn June 2020 © Copyright by Amelia Dunn 2020 Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior Amelia Dunn, Ph.D. The Rockefeller University 2020 The opioid system, comprised mainly of the three opioid receptors (kappa, mu and delta) and their endogenous neuropeptide ligands (dynorphin, endorphin and enkephalin, respectively), mediates mood and reward. Activation of the mu opioid receptor is associated with positive reward and euphoria, while activation of the kappa opioid receptor (KOR) has the opposite effect. Activation of the KOR causes a decrease in dopamine levels in reward-related regions of the brain, and can block the rewarding effects of various drugs of abuse, making it a potential drug target for addictive diseases. KOR agonists are of particular interest for the treatment of cocaine and other psychostimulant addictions, because there are currently no available medications for these diseases. Studies in humans and animals, however, have shown that activation of the KOR also causes negative side effects such as hallucinations, aversion and sedation. Several strategies are currently being employed to develop KOR agonists that block the rewarding effects of drugs of abuse with fewer side effects, including KOR agonists with unique pharmacology.
    [Show full text]
  • Targeting the Cannabinoid and Mu Opioid Receptors with Heterodimerized and Allosteric Ligands
    Targeting the cannabinoid and mu opioid receptors with heterodimerized and allosteric ligands Ph.D. Thesis Szabolcs Dvorácskó Supervisor: Dr. Csaba Tömböly Universitiy of Szeged, Faculty of Medicine Doctoral School of Theoretical Medicine Laboratory of Chemical Biology, Institute of Biochemistry Biological Research Center of the Hungarian Academy of Sciences Szeged, Hungary 2019 TABLE OF CONTENTS LIST OF PUBLICATIONS ...................................................................................................... i ABBREVIATIONS ................................................................................................................. iv ACKNOWLEDGEMENTS .................................................................................................... vi 1. Introduction .......................................................................................................................... 1 1.1. The cannabinoid system ...................................................................................................... 1 1.1.1. Cannabinoid receptors ...................................................................................................... 1 1.1.2. Lipid type endocannabinoids ........................................................................................... 2 1.1.3. Hemopressins (Pepcans), the putative peptide endocannabinoids ................................... 2 1.1.4. Phyto- and synthetic cannabinoids ................................................................................... 4 1.2. The opioid
    [Show full text]
  • Biochemical and Pharmacological Characterization of Three Opioid-Nociceptin Hybrid Peptide Ligands Reveals Substantially Differing Modes of Their Actions
    Accepted Manuscript Title: Biochemical and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions Authors: Anna I. Erdei, Adina Borbely,´ Anna Magyar, Nora´ Taricska, Andras´ Perczel, OttoZs´ ´ıros, Gyoz˝ o˝ Garab, Edina Szucs,˝ Ferenc Otv¨¨ os, Ferenc Zador,´ Mihaly´ Balogh, Mahmoud Al-Khrasani, Sandor´ Benyhe PII: S0196-9781(17)30318-2 DOI: https://doi.org/10.1016/j.peptides.2017.10.005 Reference: PEP 69842 To appear in: Peptides Received date: 24-4-2017 Revised date: 10-10-2017 Accepted date: 11-10-2017 Please cite this article as: Erdei Anna I, Borbely´ Adina, Magyar Anna, Taricska Nora,´ Perczel Andras,´ Zs´ıros Otto,´ Garab Gyoz˝ o,˝ Szucs˝ Edina, Otv¨¨ os Ferenc, Zador´ Ferenc, Balogh Mihaly,´ Al-Khrasani Mahmoud, Benyhe Sandor.Biochemical´ and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions.Peptides https://doi.org/10.1016/j.peptides.2017.10.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Biochemical and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions Running title: Opioid-like receptor labelling by bivalent peptides Anna I Erdei1, Adina Borbély2, Anna Magyar2, Nóra Taricska3, András Perczel3,4, Ottó Zsíros5, Győző Garab5, Edina Szűcs1, Ferenc Ötvös1, Ferenc Zádor1, Mihály Balogh6, Mahmoud Al-Khrasani6, Sándor Benyhe1* 1 Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, H- 6726 Szeged, Temesvári krt.
    [Show full text]
  • INTERNATIONAL NARCOTICS RESEARCH CONFERENCE 11–14 JULY 2016 Bath Assembly Rooms Bath, United Kingdom
    TODAY’S SCIENCE TOMORROW’S MEDICINES INTERNATIONAL NARCOTICS RESEARCH CONFERENCE 11–14 JULY 2016 Bath Assembly Rooms Bath, United Kingdom Programme Programme v2_mono.indd 1 01/07/2016 16:23 EXECUTIVE COMMITTEE CONFERENCE ORGANISING COMMITTEE Fred Nyberg (Sweden, President) Chris Bailey (UK) John Traynor (USA, Past-President) Eamonn Kelly (UK) Lawrence Toll (USA, Treasurer) Graeme Henderson (UK) Craig W. Stevens (USA, Information Officer) Elena Bagley (Australia) Jose Moron-Concepcion (USA) Alexis Bailey (UK) Cathy Cahill (USA) Alistair Corbett (UK) Amynah Pradhan (USA) Steve Husbands (UK) Dominique Massotte (France) Susie Ingram (USA) Christoph Stein (Germany) Dominique Massotte (France) Chris Bailey (UK) Jose Moron-Concepcion (USA) Chagi Pick (Israel) Fred Nyberg (Sweden) Paul Bigliardi (Singapore) Amynah Pradhan (USA) Kazutaka Ikeda (Japan) Christoph Stein (Germany) Contents INFORMATION FOR PARTICIPANTS 3 EXHIBITOR & SPONSOR INFORMATION 5 LOCATION MAP 8 INRC 2016 AWARDEES 9 MEETING PROGRAMME 10 ABSTRACTS 19 Follow @BritPharmSoc and @INRC2016 on Twitter Use the hashtag #INRCBath to share your thoughts and see what others are saying For more information at attending or presenting at other Society meetings find us at the registration desk, email [email protected] or visit www.bps.ac.uk 2 3 Programme v2_mono.indd 2 01/07/2016 16:23 Information for participants KEY TIMINGS Sunday 10 July 15.00–17.00 Registration (Bath Assembly Rooms) 20.00–21.30 Welcome reception (Pump Rooms) Monday 11 July 08.00 Registration 08.30 Plenary Lecture 09.30
    [Show full text]
  • A43 Discovery and Biological Evaluation of a Diphenethylamine
    APHAR 2012 Abstract Preview A43 Discovery and biological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist Mariana Spetea1, Ilona P Berzetei-Gurske2, Elena Guerrieri1, Jayapalreddy Mallareddy3, Géza Tóth3 and Helmut Schmidhammer1 1Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria; 2Biosciences Division, SRI International, Menlo Park, CA 94025, USA; 3Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6701 Szeged, Hungary E-mail: [email protected] Background: Activation of the κ opioid (KOP) receptor results in antinociceptive actions, while it is not involved in the unwanted effects including respiratory depression, dependence or abuse liability, as in the case of the µ opioid (MOP) receptor. Therefore, KOP agonists appear to possess some advantages over the most widely used MOR analgesics. Besides the analgesic activity, KOP agonists have also shown other beneficial effects such as anti-pruritic, anti-arthritic, anti-inflammatory, and neuroprotective effects. At present, the main classes of available chemically distinct KOP agonists include benzomorphans, morphinans, arylacetamides, diterpenes and peptides. Herein, we present a new molecular scaffold for KOP ligands of the class of diphenethylamines and biological investigations on in vitro and in vivo opioid activities. Methods: Synthesis of the novel KOP ligands was accomplished by multi-step syntheses. Chinese hamster ovary (CHO) cell membranes expressing human opioid receptors were used in radioligand binding and [35S]GTPγS functional assays. Antinociceptive activities were assessed in mice using the writhing test. Results: Several novel ligands were synthesized and pharmacologically evaluated. Among them, HS665 proved to be the derivative with the highest selectivity for the KOP receptor vs.
    [Show full text]
  • Development of Diphenethylamines As Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities
    molecules Review Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities Helmut Schmidhammer *, Filippo Erli, Elena Guerrieri and Mariana Spetea * Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria; fi[email protected] (F.E.); [email protected] (E.G.) * Correspondence: [email protected] (H.S.); [email protected] (M.S.) Received: 15 October 2020; Accepted: 30 October 2020; Published: 2 November 2020 Abstract: Among the opioid receptors, the kappa opioid receptor (KOR) has been gaining substantial attention as a promising molecular target for the treatment of numerous human disorders, including pain, pruritus, affective disorders (i.e., depression and anxiety), drug addiction, and neurological diseases (i.e., epilepsy). Particularly, the knowledge that activation of the KOR, opposite to the mu opioid receptor (MOR), does not produce euphoria or leads to respiratory depression or overdose, has stimulated the interest in discovering ligands targeting the KOR as novel pharmacotherapeutics. However, the KOR mediates the negative side effects of dysphoria/aversion, sedation, and psychotomimesis, with the therapeutic promise of biased agonism (i.e., selective activation of beneficial over deleterious signaling pathways) for designing safer KOR therapeutics without the liabilities of conventional KOR agonists. In this review, the development of new KOR ligands from the class of diphenethylamines is presented. Specifically, we describe the design strategies, synthesis, and pharmacological activities of differently substituted diphenethylamines, where structure–activity relationships have been extensively studied. Ligands with distinct profiles as potent and selective agonists, G protein-biased agonists, and selective antagonists, and their potential use as therapeutic agents (i.e., pain treatment) and research tools are described.
    [Show full text]
  • Synthesis, Biochemical, Pharmacological Characterization and in Silico Profile Modelling of Highly Potent Opioid Orvinol and Thevinol Derivatives
    Comparative biochemical and pharmacological investigations of various newly developed opioid receptor ligands Ph.D. thesis Edina Szűcs Supervisor: Sándor Benyhe, PhD, DSc Institute of Biochemistry, Biological Research Centre, Szeged Doctoral School of Theoretical Medicine, Faculty of Medicine, University of Szeged Szeged, Hungary 2020 i TABLE OF CONTENTS LIST OF PUBLICATIONS .......................................................................................... iii ACKNOWLEDGEMENTS ......................................................................................... vii LIST OF ABBREVIATIONS ....................................................................................... ix 1 INTRODUCTION ............................................................................................... 1 1.1 G-protein coupled receptors (GPCRs) .......................................................... 1 1.1.1 About GPCRs in general ...................................................................... 1 1.1.2 The structure of GPCRs ....................................................................... 1 1.1.3 GPCR signalling ................................................................................... 2 1.1.3.1 Gα signalling ................................................................................. 3 1.1.3.2 G signalling ................................................................................. 4 βγ 1.2 The opioid system ....................................................................................... 4 1.2.1 Poppy
    [Show full text]
  • ( 12 ) United States Patent
    US010004749B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 004, 749 B2 Hsu (45 ) Date of Patent: Jun . 26 , 2018 ( 54 ) COMPOSITION COMPRISING A ( 56 ) References Cited THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND U . S . PATENT DOCUMENTS METHODS FOR THE USE THEREOF 2002 / 0010127 A1 * 1/ 2002 Oshlack A61K 9 /0031 424 / 449 ( 71 ) Applicant : John Hsu , Rowland Heights , CA (US ) 2003 /0092701 A1 * 5 /2003 Lalley .. .. .. A61K 31/ 4745 514 /217 .02 2012 /0100107 A1 4 /2012 Mannion et al . (72 ) Inventor : John Hsu , Rowland Heights , CA (US ) 2012 /0270848 A1 10 /2012 Mannion et al. ( * ) Notice : Subject to any disclaimer , the term of this 2014 / 0030322 Al 1 / 2014 Bosse et al . patent is extended or adjusted under 35 2015 /0291597 Al 10 /2015 Mannion et al. U . S . C . 154 (b ) by 0 days. days . OTHER PUBLICATIONS (21 ) Appl . No. : 15/ 214 , 421 International Search Report and Written Opinion , PCT /US2016 / 043024 , dated Sep . 26 , 2016 . Jul. 19 , 2016 Randall , et al . , Effect of oral doaxapram on morphine induced ( 22 ) Filed : changes in the ventilatory response to carbon dioxide , Br. J Anaest , vol. 62 , 1989 , 159 - 163 . (65 ) Prior Publication Data Robson , A pharmacokinetic study of doxapram in patients and US 2017 /0020885 A1 Jan . 26 , 2017 volunteers, Br. J. Clinical Pharmac. , 1978 , vol. 7 , 81 -87 . * cited by examiner Related U . S . Application Data Primary Examiner — Bethany P Barham Assistant Examiner — Barbara S Frazier (60 ) Provisional application No . 62 / 195 ,769 , filed on Jul. ( 74 ) Attorney , Agent, or Firm — Entralta P . C . ; James W .
    [Show full text]
  • Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice Amelia D
    International Journal of Neuropsychopharmacology (2018) 21(9): 847–857 doi:10.1093/ijnp/pyy034 Advance Access Publication: April 4, 2018 Regular Research Article regular research article Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice Amelia D. Dunn*, Brian Reed,* Catherine Guariglia, Alexandra M. Dunn, Joshua M. Hillman, Mary Jeanne Kreek Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, New York. *These authors contributed equally to this work. Correspondence: Amelia Dunn, BS, BA, 1230 York Ave, Box 243, New York, NY 10065 ([email protected]). Abstract Background: The kappa opioid receptor system has been revealed as a potential pharmacotherapeutic target for the treatment of addictions to substances of abuse. Kappa opioid receptor agonists have been shown to block the rewarding and dopamine-releasing effects of psychostimulants. Recent investigations have profiled the in vivo effects of compounds biased towards G-protein-mediated signaling, with less potent arrestin-mediated signaling. The compounds studied here derive from a series of trialkylamines: N-substituted-N- phenylethyl-N-3-hydroxyphenylethyl-amine, with N-substituents including n-butyl (BPHA), methylcyclobutyl (MCBPHA), and methylcyclopentyl (MCPPHA). Methods: BPHA, MCBPHA, and MCPPHA were characterized in vitro in a kappa opioid receptor-expressing cell line in binding assays and functional assays. We also tested the compounds in C57BL6 mice, assaying incoordination with rotarod, as well as circulating levels of the neuroendocrine kappa opioid receptor biomarker, prolactin. Results: BPHA, MCBPHA, and MCPPHA showed full kappa opioid receptor agonism for G-protein coupling compared with the reference compound U69,593.
    [Show full text]